Role of anti-EGFR target therapy in colorectal carcinoma

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 1, 2012, Pages 12-22

  Enrique, Aranda Aguilar ^a   Gema, Pulido Cortijo ^a   Jeronimo, Jimenez Castro ^a   María Auxiliadora, Gomez Espana ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Cetuximab; Colorectal carcinoma; EGFR; Gene mutation; KRAS; Molecular medicine; Monoclonal antibody; Panitumumab; Review

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MONOCLONAL ANTIBODY; MUTANT PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSFORMING GROWTH FACTOR ALPHA; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; GENE MUTATION; HUMAN; HYPOMAGNESEMIA; INTENTION TO TREAT ANALYSIS; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTO ONCOGENE; COLORECTAL TUMOR; DRUG ANTAGONISM; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84860856668     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e357     Document Type: Article

References (37)

1. Jemal, A., R. Siegel, E. Ward, Y. Hao, J. Xu & M. J. Thun: Cancer statistics, 2009. CA Cancer J Clin, 59, 225- 49 (2009)
2. Mendelsohn, J. & J. Baselga: Epidermal growth factor receptor targeting in cancer. Semin Oncol, 33, 369-85 (2006)
3. Lemmon, M. A. & J. Schlessinger: Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci, 19, 459-63 (1994)
4. Khosravi-Far, R. & C. J. Der: The Ras signal transduction pathway. Cancer Metastasis Rev, 13, 67-89 (1994)
5. Finkelstein, S. D., R. Sayegh, S. Christensen & P. A. Swalsky: Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer, 71, 3827-38 (1993)
6. Bos, J. L., E. R. Fearon, S. R. Hamilton, M. Verlaan-de Vries, J. H. van Boom, A. J. van der Eb & B. Vogelstein: Prevalence of ras gene mutations in human colorectal cancers. Nature, 327, 293-7 (1987)
7. Bazan, V., V. Agnese, S. Corsale, V. Calo, M. R. Valerio, M. A. Latteri, S. Vieni, N. Grassi, G. Cicero, G. Dardanoni, R. M. Tomasino, G. Colucci, N. Gebbia & A. Russo: Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann Oncol, 16 Suppl 4, iv50-55 (2005)
8. Etienne-Grimaldi, M. C., J. L. Formento, M. Francoual, E. Francois, P. Formento, N. Renee, P. Laurent-Puig, M. Chazal, D. Benchimol, J. R. Delpero, C. Letoublon, D. Pezet, J. F. Seitz & G. Milano: K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res, 14, 4830-5 (2008)
9. De Roock, W., H. Piessevaux, J. De Schutter, M. Janssens, G. De Hertogh, N. Personeni, B. Biesmans, J. L. Van Laethem, M. Peeters, Y. Humblet, E. Van Cutsem & S. Tejpar: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol, 19, 508-15 (2008)
10. Di Fiore, F., F. Blanchard, F. Charbonnier, F. Le Pessot, A. Lamy, M. P. Galais, L. Bastit, A. Killian, R. Sesboue, J. J. Tuech, A. M. Queuniet, B. Paillot, J. C. Sabourin, F. Michot, P. Michel & T. Frebourg: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer, 96, 1166-9 (2007)
11. Khambata-Ford, S., C. R. Garrett, N. J. Meropol, M. Basik, C. T. Harbison, S. Wu, T. W. Wong, X. Huang, C. H. Takimoto, A. K. Godwin, B. R. Tan, S. S. Krishnamurthi, H. A. Burris, 3rd, E. A. Poplin, M. Hidalgo, J. Baselga, E. A. Clark & D. J. Mauro: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol, 25, 3230-7 (2007)
12. Lievre, A., J. B. Bachet, V. Boige, A. Cayre, D. Le Corre, E. Buc, M. Ychou, O. Bouche, B. Landi, C. Louvet, T. Andre, F. Bibeau, M. D. Diebold, P. Rougier, M. Ducreux, G. Tomasic, J. F. Emile, F. Penault-Llorca & P. Laurent-Puig: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol, 26, 374-9 (2008)
13. Benvenuti, S., A. Sartore-Bianchi, F. Di Nicolantonio, C. Zanon, M. Moroni, S. Veronese, S. Siena & A. Bardelli: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res, 67, 2643-8 (2007)
14. Lievre, A., J. B. Bachet, D. Le Corre, V. Boige, B. Landi, J. F. Emile, J. F. Cote, G. Tomasic, C. Penna, M. Ducreux, P. Rougier, F. Penault-Llorca & P. Laurent-Puig: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res, 66, 3992-5 (2006)
15. Baselga, J., D. Pfister, M. R. Cooper, R. Cohen, B. Burtness, M. Bos, G. D'Andrea, A. Seidman, L. Norton, K. Gunnett, J. Falcey, V. Anderson, H. Waksal & J. Mendelsohn: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol, 18, 904-14 (2000)
16. Saltz L, R. M., Hochster H, et al. : Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer) CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001:20 (2001)
17. Saltz, L. B., N. J. Meropol, P. J. Loehrer, Sr., M. N. Needle, J. Kopit & R. J. Mayer: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 22, 1201-8 (2004)
18. Cunningham, D., Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau & E. Van Cutsem: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351, 337-45 (2004)
19. Bokemeyer, C., I. Bondarenko, A. Makhson, J. T. Hartmann, J. Aparicio, F. de Braud, S. Donea, H. Ludwig, G. Schuch, C. Stroh, A. H. Loos, A. Zubel & P. Koralewski: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol, 27, 663-71 (2009)
20. Raoul, J. L., J. L. Van Laethem, M. Peeters, C. Brezault, F. Husseini, L. Cals, J. Nippgen, A. H. Loos & P. Rougier: Cetuximab in combination with irinotecan/5- fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer, 9, 112 (2009)
21. Tabernero, J., E. Van Cutsem, E. Diaz-Rubio, A. Cervantes, Y. Humblet, T. Andre, J. L. Van Laethem, P. Soulie, E. Casado, C. Verslype, J. S. Valera, G. Tortora, F. Ciardiello, O. Kisker & A. de Gramont: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol, 25, 5225-32 (2007)
22. Van Cutsem, E., C. H. Kohne, E. Hitre, J. Zaluski, C. R. Chang Chien, A. Makhson, G. D'Haens, T. Pinter, R. Lim, G. Bodoky, J. K. Roh, G. Folprecht, P. Ruff, C. Stroh, S. Tejpar, M. Schlichting, J. Nippgen & P. Rougier: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 360, 1408-17 (2009)
23. Sobrero, A. F., J. Maurel, L. Fehrenbacher, W. Scheithauer, Y. A. Abubakr, M. P. Lutz, M. E. Vega- Villegas, C. Eng, E. U. Steinhauer, J. Prausova, H. J. Lenz, C. Borg, G. Middleton, H. Kroning, G. Luppi, O. Kisker, A. Zubel, C. Langer, J. Kopit & H. A. Burris, 3rd: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol, 26, 2311-9 (2008)
24. Tejpar S, P. M., Humblet Y, et al: Relationship of efficacy with K-RAS status wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan(q2w) and escalating doses of cetuximab(q1w): The EVEREST experience (preliminary data). J Clin Oncol (2008)
25. Hecht, J. R., A. Patnaik, J. Berlin, A. Venook, I. Malik, S. Tchekmedyian, L. Navale, R. G. Amado & N. J. Meropol: Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer, 110, 980-8 (2007)
26. Van Cutsem, E., M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, B. Neyns, J. L. Canon, J. L. Van Laethem, J. Maurel, G. Richardson, M. Wolf & R. G. Amado: Openlabel phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. J Clin Oncol, 25, 1658-64 (2007)
27. Amado, R. G., M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D. J. Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky, S. D. Patterson & D. D. Chang: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 26, 1626- 34 (2008)
28. Hecht JR, M. E., Baranda J, et al: Panitumumab efficacy in patients with metastatic colorectal cancer with low or undetecTable levels or epidermal growth factor receptor: final efficacy and K-RAS analysis. Program and abstracts of the 2008 Gastrointestinal Cancers Symposium(GCS) (2008)
29. Saltz, L. B., H. J. Lenz, H. L. Kindler, H. S. Hochster, S. Wadler, P. M. Hoff, N. E. Kemeny, E. M. Hollywood, M. Gonen, M. Quinones, M. Morse & H. X. Chen: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND- 2 study. J Clin Oncol, 25, 4557-61 (2007)
30. Hecht, J. R., E. Mitchell, T. Chidiac, C. Scroggin, C. Hagenstad, D. Spigel, J. Marshall, A. Cohn, D. McCollum, P. Stella, R. Deeter, S. Shahin & R. G. Amado: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol, 27, 672-80 (2009)
31. Tol, J., M. Koopman, A. Cats, C. J. Rodenburg, G. J. Creemers, J. G. Schrama, F. L. Erdkamp, A. H. Vos, C. J. van Groeningen, H. A. Sinnige, D. J. Richel, E. E. Voest, J. R. Dijkstra, M. E. Vink-Borger, N. F. Antonini, L. Mol, J. H. van Krieken, O. Dalesio & C. J. Punt: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med, 360, 563-72 (2009)
32. Di Nicolantonio, F., M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena & A. Bardelli: Wildtype BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 26, 5705-12 (2008)
33. Samuels, Y., L. A. Diaz, Jr., O. Schmidt-Kittler, J. M. Cummins, L. Delong, I. Cheong, C. Rago, D. L. Huso, C. Lengauer, K. W. Kinzler, B. Vogelstein & V. E. Velculescu: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell, 7, 561-73 (2005)
34. Jhawer, M., S. Goel, A. J. Wilson, C. Montagna, Y. H. Ling, D. S. Byun, S. Nasser, D. Arango, J. Shin, L. Klampfer, L. H. Augenlicht, R. Perez-Soler & J. M. Mariadason: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res, 68, 1953-61 (2008)
35. Frattini, M., P. Saletti, E. Romagnani, V. Martin, F. Molinari, M. Ghisletta, A. Camponovo, L. L. Etienne, F. Cavalli & L. Mazzucchelli: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer, 97, 1139-45 (2007)
36. Loupakis, F., L. Pollina, I. Stasi, A. Ruzzo, M. Scartozzi, D. Santini, G. Masi, F. Graziano, C. Cremolini, E. Rulli, E. Canestrari, N. Funel, G. Schiavon, I. Petrini, M. Magnani, G. Tonini, D. Campani, I. Floriani, S. Cascinu & A. Falcone: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol, 27, 2622-9 (2009)
37. Perrone, F., A. Lampis, M. Orsenigo, M. Di Bartolomeo, A. Gevorgyan, M. Losa, M. Frattini, C. Riva, S. Andreola, E. Bajetta, L. Bertario, E. Leo, M. A. Pierotti & S. Pilotti: PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol, 20, 84-90 (2009)